Core Insights - Actuate Therapeutics, Inc. has launched an expanded research initiative to evaluate the combination of its GSK-3β inhibitor elraglusib with emerging RAS-targeted therapies to enhance treatment for difficult-to-treat cancers [1][2] Group 1: Research Initiative - The initiative aims to address adaptive resistance mechanisms in RAS-targeted therapies, which are significant barriers to achieving durable responses in patients [2] - GSK-3β inhibition may enhance RAS-targeted therapies by suppressing downstream survival signaling and resistance pathways, potentially improving clinical outcomes in RAS-driven cancers [2][6] Group 2: Elraglusib Overview - Elraglusib is a highly selective GSK-3β inhibitor with potential applications across various oncology indications, including pancreatic cancer, melanoma, colorectal cancer, and sarcoma [3] - The investigational drug has been administered to over 500 patients and is currently in a Phase 2 trial for metastatic pancreatic cancer [3] Group 3: Combination Strategy - The combination strategy aims to block proliferative signaling through RAS inhibition while disrupting tumor survival pathways via elraglusib's GSK-3β inhibition, potentially enhancing apoptotic signaling [4] - The program will include in-vitro studies, in-vivo tumor regression and survival studies, and translational biomarker analysis, with initial data expected in Q2 2026 [5][6] Group 4: Future Development - The company is collaborating with leading academic institutions and potential industry partners to advance elraglusib as a foundational component of next-generation treatment paradigms for RAS-driven cancers [6] - Preclinical combination results are anticipated in the second half of 2026, which will inform future clinical development plans [8]